These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24706498)

  • 1. Effect of eplerenone in percutaneous coronary intervention-treated post-myocardial infarction patients with left ventricular systolic dysfunction: a subanalysis of the EPHESUS trial.
    Iqbal J; Fay R; Adlam D; Squire I; Parviz Y; Gunn J; Pitt B; Zannad F
    Eur J Heart Fail; 2014 Jun; 16(6):685-91. PubMed ID: 24706498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial.
    Adamopoulos C; Ahmed A; Fay R; Angioi M; Filippatos G; Vincent J; Pitt B; Zannad F;
    Eur J Heart Fail; 2009 Nov; 11(11):1099-105. PubMed ID: 19875410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
    Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS.
    O'Keefe JH; Abuissa H; Pitt B
    Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Olivier A; Girerd N; Michel JB; Ketelslegers JM; Fay R; Vincent J; Bramlage P; Pitt B; Zannad F; Rossignol P;
    Int J Cardiol; 2017 Aug; 241():344-350. PubMed ID: 28284500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).
    Pitt B; Bakris G; Ruilope LM; DiCarlo L; Mukherjee R;
    Circulation; 2008 Oct; 118(16):1643-50. PubMed ID: 18824643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.
    Pitt B; White H; Nicolau J; Martinez F; Gheorghiade M; Aschermann M; van Veldhuisen DJ; Zannad F; Krum H; Mukherjee R; Vincent J;
    J Am Coll Cardiol; 2005 Aug; 46(3):425-31. PubMed ID: 16053953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
    Iraqi W; Rossignol P; Angioi M; Fay R; Nuée J; Ketelslegers JM; Vincent J; Pitt B; Zannad F
    Circulation; 2009 May; 119(18):2471-9. PubMed ID: 19398668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction.
    Gheorghiade M; Khan S; Blair JE; Harinstein ME; Krum H; Mukherjee R; Pitt B;
    Am Heart J; 2009 Sep; 158(3):437-43. PubMed ID: 19699868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction--an analysis of the EPHESUS study from a Swiss perspective.
    Szucs TD; Holm MV; Schwenkglenks M; Zhang Z; Weintraub WS; Burnier M; Erne P
    Cardiovasc Drugs Ther; 2006 Jun; 20(3):193-204. PubMed ID: 16775667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone : a review of its use in left ventricular systolic dysfunction and heart failure after acute myocardial infarction.
    Keating GM; Plosker GL
    Drugs; 2004; 64(23):2689-707. PubMed ID: 15537370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study.
    Rossignol P; Cleland JG; Bhandari S; Tala S; Gustafsson F; Fay R; Lamiral Z; Dobre D; Pitt B; Zannad F
    Circulation; 2012 Jan; 125(2):271-9. PubMed ID: 22128223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 16. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
    Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure.
    Weintraub WS; Zhang Z; Mahoney EM; Kolm P; Spertus JA; Caro J; Ishak J; Goldberg R; Tooley J; Willke R; Pitt B
    Circulation; 2005 Mar; 111(9):1106-13. PubMed ID: 15723981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of magnesium alterations in patients with a myocardial infarction and left ventricular dysfunction: insights from the EPHESUS trial.
    Martens P; Ferreira JP; Vincent J; Abreu P; Busselen M; Mullens W; Tang WHW; Böhm M; Pitt B; Zannad F; Rossignol P
    Eur Heart J Acute Cardiovasc Care; 2022 Feb; 11(2):148-159. PubMed ID: 35021200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.